Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
The American Board of Internal Medicine (ABIM) announced that certified physicians who have a Maintenance of Certification (MOC) requirement due in 2020 will now have until the end of 2021 to complete it.
Remunity is indicated for continuous subcutaneous delivery of Remodulin to treat pulmonary arterial hypertension in patients ≥22 years of age.
The designation is based on data from a phase 2 trial that included 116 patients with confirmed Staphylococcus aureus bacteremia including endocarditis.
AstraZeneca is discontinuing a phase 3 trial evaluating Epanova in patients with mixed dyslipidemia who are at high risk of CVD.
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
The FDA has granted Breakthrough Therapy designation to rilonacept for the treatment of recurrent pericarditis.
Vericiguat (Merck and Bayer) reduced the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure, according to new phase 3 data.
The FDA has granted Fast Track designation to ASP1128, an investigational treatment for patients at increased risk of developing moderate to severe AKI after CABG and/or valve surgery.
Katerzia (amlodipine) Oral Suspension, 1mg/mL is now commercially available.
